Publikationen in Zusammenarbeit mit Forschern von Dana–Farber Cancer Institute (4)

2018

  1. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

    Leukemia, Vol. 32, Núm. 12, pp. 2546-2557

2017

  1. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

    BMC Cancer, Vol. 17, Núm. 1

  2. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

    Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597

2015

  1. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    Blood, Vol. 126, Núm. 3, pp. 291-299